iShares Global Healthcare ETF (IXJ)
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?
IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?
The Invesco Nasdaq Biotechnology ETF (IBBQ) carries a lower expense ratio than the iShares Global Healthcare ETF (IXJ). IXJ offers broad global exposure across the healthcare sector, while IBBQ is concentrated exclusively in Nasdaq-listed biotechnology and pharmaceutical companies.
IXJ: Healthcare Sector Dashboard For June
Healthcare equipment appears undervalued, while life science tools show weak quality. iShares Global Healthcare ETF provides global healthcare exposure but has underperformed the U.S.-focused XLV both long and short term with a higher expense ratio. 10 stocks cheaper than their peers in June.
Leo Wealth LLC Has $14.30 Million Stock Holdings in iShares Global Healthcare ETF $IXJ
Leo Wealth LLC grew its stake in shares of iShares Global Healthcare ETF (NYSEARCA:IXJ) by 59.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 146,798 shares of the company's stock after acquiring an additional 54,516 shares during the quarter. iShares Global
IXJ: Healthcare Sector Dashboard For February
While the broad market is overpriced, value still exists in the healthcare sector, especially in healthcare providers and healthcare equipment. iShares Global Healthcare ETF offers global healthcare exposure with slightly better fundamentals and lower company-specific risk than XLV. 10 stocks cheaper than their peers in February.
Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond
After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.
iShares Global Healthcare ETF (NYSEARCA:IXJ) Hits New 52-Week High – Here’s Why
Shares of iShares Global Healthcare ETF (NYSEARCA:IXJ - Get Free Report) hit a new 52-week high on Friday. The company traded as high as $99.48 and last traded at $98.0080, with a volume of 122 shares. The stock had previously closed at $98.09. iShares Global Healthcare ETF Stock Performance The stock has a market
Osaic Holdings Inc. Has $2.79 Million Stake in iShares Global Healthcare ETF $IXJ
Osaic Holdings Inc. boosted its position in shares of iShares Global Healthcare ETF (NYSEARCA:IXJ) by 27.7% during the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,370 shares of the company's stock after purchasing an additional 7,014 shares during the period. Osaic
IXJ: Healthcare Sector Dashboard For October
Healthcare providers and pharmaceuticals/biotechnology subsectors are undervalued versus 11-year averages, with pharma/biotech also showing strong quality metrics. iShares Global Healthcare ETF (IXJ): an alternative to XLV with international diversification and better fundamentals. 10 healthcare stocks cheaper than their peers in October.
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
On IXJ, A Contradiction Has Emerged That Is Too Big To Be Ignored
Tough moment for healthcare: low momentum, high volatility, and downgraded EPS. It is evident when looking at the IXJ ETF, focused on global healthcare: 70% US, 30% international. But relative valuations have remained attractive: healthcare trades at a forward P/E in the 30th percentile of the past 30 years' distribution.
IXJ: A Bet On Global Healthcare Recovery
IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs for a more balanced risk/reward profile. The fund's heavy allocation to pharmaceuticals and biotechnology targets high-growth areas like obesity drugs, oncology, and AI-driven healthcare equipment. Despite a higher expense ratio and currency/regulatory risks, IXJ's global diversification and defensive sector positioning justify its buy rating.
IXJ: Healthcare Sector Dashboard For May
This article provides a top-down analysis of the healthcare sector using value, quality, and momentum metrics. Healthcare providers and pharmaceuticals/biotechnology are the most compelling subsectors based on value and quality scores. IXJ ETF offers global healthcare exposure but remains concentrated in U.S. stocks and top holdings; it has trailed XLV in long-term returns but is more diversified.
IXJ: Healthcare Sector Dashboard For February
This article provides a top-down analysis of the healthcare sector, focusing on fundamental and momentum metrics. The healthcare sector is currently overvalued by about 13% relative to 11-year averages, with pharmaceuticals/biotechnology being the most overvalued. IXJ offers global healthcare exposure but is heavily weighted in U.S. companies and has underperformed XLV for 10 years.
IXJ: Healthcare Sector Dashboard For November
The healthcare sector is overvalued by 18% relative to 11-year averages, with pharmaceuticals/biotechnology and healthcare equipment most overpriced. IXJ offers global healthcare exposure with lower concentration in top holdings compared to XLV, but still has 72% of assets in U.S. companies. 10 stocks cheaper than their peers in November.
IXJ: Healthcare Sector Dashboard For August
Monthly article series showing healthcare industry metrics. The healthcare sector is overvalued by about 18% relative to 11-year averages. The most overvalued subsector is pharmaceuticals and biotechnology.
IXJ: Growth Expected To Be Very Strong In The Next Few Years
iShares Global Healthcare ETF has underperformed the S&P 500 index in the past few years. IXJ has lower volatility and downside risk compared to the broader market. The healthcare sector is expected to have strong earnings growth in 2024 and 2025, making IXJ an attractive investment.